» Articles » PMID: 37103655

Denosumab for Giant Cell Tumors of Bone from 2010 to 2022: a Bibliometric Analysis

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2023 Apr 27
PMID 37103655
Authors
Affiliations
Soon will be listed here.
Abstract

Giant cell tumors of the bone (GCTB) are considered moderately malignant bone tumors. Denosumab, as a neoadjuvant therapy, provides new possibilities for treating GCTB. However, even after multiple studies and long-term clinical trials, there are limitations in the treatment process. Research data and Medical Subject Headings terms related to denosumab and GCTB were collected from January 2010 to October 2022 using the Web of Science and MeSH ( https://meshb.nlm.nih.gov ) browsers. These data were imported into CiteSpace and VOSviewer softwares for bibliometric analysis. Overall, 445 publications on denosumab and GCTB were identified. Over the last 12 years, the growth rate of the total number of publications has remained relatively stable. The USA published the highest number of articles (83) and had the highest centrality (0.42). Amgen Inc. and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) First Ortoped Rizzoli were identified as the most influential institutions. Many authors have made outstanding contributions to this field. Lancet Oncology had the highest journal impact factor (54.433). Local recurrence and drug dosage are current research hotspots, and future development trends will mainly focus on prognostic markers of GCTB and the development of new therapies. Further research is required to analyze denosumab's safety and efficacy and understand its local recurrence of GCTB, to identify the optimal dose. Future progress in this field will likely focus on exploring new diagnostic and recurrence markers to monitor disease progression and examine new therapeutic targets and treatment strategies.

Citing Articles

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?.

de la Calva C, Angulo M, Gonzalez-Rojo P, Peiro A, Machado P, Cebrian J Cancer Rep (Hoboken). 2025; 8(1):e70117.

PMID: 39797695 PMC: 11726647. DOI: 10.1002/cnr2.70117.


[One case of recurrent giant cell tumor of the larynx and literature review].

Liu Y, Xu K, Feng Q, Lu X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(11):1073-1076.

PMID: 39534902 PMC: 11879714. DOI: 10.13201/j.issn.2096-7993.2024.11.015.


Denosumab combined with microwave ablation excisional scraping for giant cell tumor of the thoracic spine: a case report and literature review.

Miao Z, Han Z, Zheng K, Xu M, Yu X, Han C Front Oncol. 2024; 14:1402550.

PMID: 39364313 PMC: 11446914. DOI: 10.3389/fonc.2024.1402550.


A bibliometric analysis based on hotspots and frontier trends of positron emission tomography/computed tomography utility in bone and soft tissue sarcoma.

Xiang F, Zhang Y, Tan X, Zhang J, Li T, Yan Y Front Oncol. 2024; 14:1344643.

PMID: 38974238 PMC: 11224451. DOI: 10.3389/fonc.2024.1344643.


Giant Cell Tumor of the Inferior Turbinate in a 12-Year-Old Child: First Case Report.

Linxweiler M, Remke M, Straub B, Schick B OTO Open. 2024; 8(2):e165.

PMID: 38938508 PMC: 11208738. DOI: 10.1002/oto2.165.

References
1.
Choi J, Ro J . The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2020; 28(1):44-58. DOI: 10.1097/PAP.0000000000000284. View

2.
Liede A, Bach B, Stryker S, Hernandez R, Sobocki P, Bennett B . Regional variation and challenges in estimating the incidence of giant cell tumor of bone. J Bone Joint Surg Am. 2014; 96(23):1999-2007. DOI: 10.2106/JBJS.N.00367. View

3.
Chan C, Adler Z, Reith J, Gibbs Jr C . Risk factors for pulmonary metastases from giant cell tumor of bone. J Bone Joint Surg Am. 2015; 97(5):420-8. DOI: 10.2106/JBJS.N.00678. View

4.
Sanjay B, Sim F, Unni K, Mcleod R, Klassen R . Giant-cell tumours of the spine. J Bone Joint Surg Br. 1993; 75(1):148-54. DOI: 10.1302/0301-620X.75B1.8421014. View

5.
Goldring S, Roelke M, Petrison K, Bhan A . Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 1987; 79(2):483-91. PMC: 424109. DOI: 10.1172/JCI112838. View